Dr. Novack will be speaking at the Spring 2017 meeting of the Boston Area Pharmacology / Toxicology Group meeting on 7 April 2017. His topic is “Ophthalmic Product Development – from Preclinical to Efficacy Outcomes”. For those interested, here is the Eventbrite link for registration.
Dr. Novack attended the American Glaucoma Society meeting in Coronado (San Diego) 2-5 March 2017. He was an author on a paper on the aqueous humor dynamics of netarsudil, an topical ocular hypotensive drug currently in clinical trials for the treatment of glaucoma.
Dr. Novack attended the first Sonoma Eye meeting on ocular inflammation. Together with colleague Dr. Ron Neumann, he gave a presentation on the patient and investor perspective on new uveitis therapies.
At Glaucoma Research Foundation‘s New Horizons Forum in San Francisco. Dr. Richard Lewis and Dr. Novack moderated a session with Dr. Wiley Chambers (CDER) and Dr. Tieuvi Nguyen (CDRH) in discussion of current ophthalmic issues at FDA.
I just returned from Hawaiian Eye in Kauai. The presentations are aimed at real world clinical practice. I experienced the warmth of long-time colleagues. It’s truly impressive how many of the attendees were people with whom I have worked on new products over the past 30+ years. In a restaurant, a waiter commented “Are you here with a convention? Do you all know each other? I’ve never seen so much table-hopping”.
I was in San Francisco for the annual J P Morgan biomedical meeting. It was very rainy and windy, which made it challenging for the attendees as they transited between hotels and meetings. It seemed to me that ophthalmology is still hot, at least as judged by the many ophthalmic colleagues I saw in hotel lobbies, coffee shops and restaurants. The changing role for academic research was also evident in that I saw at least 3 full-time professors as well!